"…it took years of younger men being diagnosed [with prostate cancer] to call attention to the fact that it’s not just a disease of older men."
— Dr Janet L. Stanford
/content/dam/www/people-profile-photos/s/janet-stanford/janet-stanford-d.jpg
Stanford
Janet L. Stanford, PhD, MPH
- Professor Emeritus, Epidemiology, Public Health Sciences Division, Fred Hutch
- Professor (Research), Epidemiology, University of Washington School of Public Health
- Adjunct Professor, Urology, University of Washington School of Medicine
Background
Dr. Janet L. Stanford is a founding member of the Program in Prostate Cancer Research at Fred Hutch, which aims to understand the causes and underlying biology of prostate cancer to develop new prevention approaches, treatments and cures. Dr. Stanford, a cancer epidemiologist, studies the role of environmental, lifestyle and genetic risk factors in prostate cancer development, disease progression and cancer-specific mortality. She also studies quality-of-life outcomes after diagnosis and treatment of prostate cancer, and genetic alterations, or mutations, that may be useful as biomarkers for predicting prostate cancer risk and aggressiveness. Dr. Stanford has led landmark studies, including finding that higher consumption of cruciferous vegetables, moderate intake of red wine and regular use of aspirin are each associated with reduced risks of the disease. She also found that heavy, long-term cigarette smoking increases the risk of prostate cancer, but that risk declines for those who quit.
Education
PhD, Epidemiology, Johns Hopkins University, 1986
MPH, Emory University, 1982
BSN, Georgia State University, 1980
Research Interests
The role of environmental, lifestyle and genetic risk factors in relation to prostate cancer etiology, disease progression, and cancer-specific mortality; functional and quality of life outcomes after diagnosis and treatment of prostate cancer; germline genetic and tumor somatic alterations that may be useful for risk stratification or as biomarkers for predicting risk or adverse prostate cancer patient outcomes.